Table 1.
Na (%) | |
---|---|
Age (Years) | |
Median (range) | 57 (22–73) |
Gender | |
Male | 7 (29) |
Female | 17 (71) |
Race | |
White | 19 (83) |
Black | 3 (13) |
Asian | 1 (4) |
Unknown | 1 (4) |
Performance status | |
0 | 10 (42) |
1 | 13 (54) |
2 | 1 (4) |
Weight loss in previous 6 months | |
<5% of body weight | 22 (92) |
5–10% of body weight | 2 (8) |
Primary site | |
Oral tongue | 1 (4) |
Floor of mouth | 1 (4) |
Hard palate | 3 (13) |
Nasopharynx, NOS | 2 (8) |
Salivary glands, NOS | 1 (4) |
Parotid | 4 (17) |
Submaxillary | 1 (4) |
Ethmoid | 1 (4) |
Nasal cavity | 1 (4) |
More than one site | 3 (12) |
Other | 6 (25) |
Primary site status at study entry | |
Eradicated, no recurrence | 6 (25) |
Eradicated, but recurred locally | 5 (21) |
Residual disease after prior therapy | 12 (50) |
Untreated | 1 (4) |
Status of regional lymph nodes | |
Never involved | 14 (64) |
Never involved, but removed prophylactically | 3 (14) |
Involved nodes eradicated | 2 (9) |
Involved nodes eradicated, but new involvement | 1 (4) |
Involved nodes not treated | 2 (9) |
Unknown | 2 |
Metastatic site involvement | |
Lung | 22 (92) |
Liver | 7 (31) |
Bone | 1 (4) |
Soft tissue | 2 (8) |
Prior Treatment | |
Chemotherapy | 10 (42) |
Radiation therapy | 23 (96) |
Surgery | 21 (86) |
except for age where actual age is shown.
NOS, not otherwise specified